The Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block
NCT ID: NCT06370949
Last Updated: 2024-04-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
84 participants
OBSERVATIONAL
2024-05-01
2024-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bupivacaine With Dexmedetomidine Versus Bupivacaine Alone for Transversus Abdominis Plane Block in Caesarean Section
NCT06292273
The Safety of Ropivacaine TAP Block Combined With Intravenous Lidocaine in Patients Undergoing Colorectal Cancer Surgery
NCT06006026
Transversus Abdominis Plane Catheter: a Study of Method
NCT01395043
Intrathecal Ketamine, Dexmedetomidine and Both With Bupivacaine for Postoperative Abdominal Cancer Surgery Pain
NCT02455609
Bupivacaine With or Without Dexmedetomidine for Postoperative Pain Relief in Abdominal Surgery
NCT07285083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The advantages of TAP block include being less invasive than epidural analgesia, lower incidence of hypotension, and shorter hospital stay. Due to these advantages, TAP block has become a widely preferred method.
Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries. The study will be conducted in a tertiary oncology hospital in Turkey and 84 colorectal cancer patients will be included.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
bupivacaine
Ultrasonography (USG) guided bilateral TAP block:20 ml %0,25 concentration bupivacain
Bupivacain
Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
bupivacaine+dexmedetomidine
Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
bupivacain+dexmedetomidine
Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bupivacain
Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
bupivacain+dexmedetomidine
Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* undergoing colorectal cancer surgery
Exclusion Criteria
* bleeding anomalies
* infection in TAP block area
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Beyza Seker
Resident Anaesthesiologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Beyza Seker, MD
Role: PRINCIPAL_INVESTIGATOR
Resident MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Turkey Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital
Ankara, Cankaya, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-01/17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.